Literature DB >> 22192286

Suppression of erythropoiesis in patients with chronic heart failure and anaemia of unknown origin: evidence of an immune basis.

Darlington O Okonko1, Stephen B Marley, Stefan D Anker, Philip A Poole-Wilson, Myrtle Y Gordon.   

Abstract

AIMS: Anaemia is a prevalent and adverse comorbidity in chronic heart failure (CHF) but its origins are frequently elusive. Diffuse inflammation is also prominent in CHF and a potent inhibitor of erythrocyte production. We tested the hypothesis that unexplained anaemia in CHF might be subsequent to diminished erythropoiesis as a result of an immune-mediated suppression of erythroid colony formation.
METHODS: We studied 61 CHF patients and 20 healthy control subjects. Circulating primitive haematopoietic (CD34(+)) and erythroid precursor cells were quantified by flow cytometry. Circulating erythroid progenitors (BFU-E) were cultured in methylcellulose in the presence and absence of monocytes and sera, and with anti-TNFα neutralising antibodies.
RESULTS: Despite higher erythropoietin levels, anaemic patients exhibited lower absolute reticulocyte counts and reticulocyte production indices (P<0.001) than non-anaemic patients and healthy controls. Diminished erythropoiesis was paralleled by attenuated circulating CD34(+), erythroid progenitor and precursor cells in anaemic patients (all P<0.01). Depletion of monocytes from cultures derived only from anaemic patients enhanced BFU-E growth (P=0.03). Only the addition of monocytes and sera from anaemic patients suppressed autologous or allogeneic BFU-E colony formation (P=0.02). Serum TNFα levels were highest in anaemic patients and anti-TNFα neutralising antibodies partly abrogated the inhibitory effects of anaemic sera on erythroid colony growth (P=0.03).
CONCLUSION: Unexplained anaemia in patients with CHF results partly from suppressed erythropoiesis and monocytes, via a direct effect of TNFα on erythroid cells, orchestrate a degree of this suppression.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22192286     DOI: 10.1016/j.ijcard.2011.11.081

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  7 in total

1.  Heme levels are increased in human failing hearts.

Authors:  Arineh Khechaduri; Marina Bayeva; Hsiang-Chun Chang; Hossein Ardehali
Journal:  J Am Coll Cardiol       Date:  2013-03-06       Impact factor: 24.094

2.  Anemia in heart failure patients.

Authors:  Michael G Alexandrakis; George Tsirakis
Journal:  ISRN Hematol       Date:  2012-03-25

Review 3.  Prognostic value of red blood cell distribution width for patients with heart failure: a systematic review and meta-analysis of cohort studies.

Authors:  Yuan-Lan Huang; Zhi-De Hu; Shi-Jian Liu; Yi Sun; Qin Qin; Bao-Dong Qin; Wei-Wei Zhang; Jian-Rong Zhang; Ren-Qian Zhong; An-Mei Deng
Journal:  PLoS One       Date:  2014-08-18       Impact factor: 3.240

Review 4.  Red Blood Cell Distribution Width: A Novel Predictive Indicator for Cardiovascular and Cerebrovascular Diseases.

Authors:  Ning Li; Heng Zhou; Qizhu Tang
Journal:  Dis Markers       Date:  2017-09-06       Impact factor: 3.434

5.  Association between red blood cell distribution width and in-hospital mortality in acute myocardial infarction.

Authors:  Sulan Huang; Quan Zhou; Ning Guo; Zhixiang Zhang; Li Luo; Yanlan Luo; Zuoan Qin; Liangqing Ge
Journal:  Medicine (Baltimore)       Date:  2021-04-16       Impact factor: 1.817

6.  Clinical significance of red blood cell distribution width in the prediction of mortality in patients on peritoneal dialysis.

Authors:  In O Sun; Byung Ha Chung; Hyun Ju Yoon; Jeong Ho Kim; Bum Soon Choi; Cheol Whee Park; Yong Soo Kim; Chul Woo Yang; Kwang Young Lee
Journal:  Kidney Res Clin Pract       Date:  2016-05-24

7.  Clinical characteristics of sepsis-induced acute kidney injury in patients undergoing continuous renal replacement therapy.

Authors:  A Young Cho; Hyun Ju Yoon; Kwang Young Lee; In O Sun
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.